Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by StevenBirchon Oct 24, 2023 9:15pm
225 Views
Post# 35699327

RE:Poppycock!

RE:Poppycock!It's funny, my takeaway from the second last news release where HC granted a CTA-A for the optimization of Phase II so that patients could receive a maintenance treatment was a further positive signal about the safety of the drug/treatment. People here always mentioned the possibility of extra treatments to possibly trigger a response. Dr. Mandel says TLT looks forward to sharing additional safety and efficacy data next month. Maybe we are just not as smart as those guys but they keep claiming to own a stock they don't like.


Rumpl3StiltSkin wrote: There is nothing in the last three press releases that suggest any extra time is needed for BTD/preBTD.
Other than compiling data for this resubmission, which TLT might have done already, I see nothing in either release to suggest that BTD will be delayed significantly. The submission of preBTD approval only takes a few working days, usually. The FDA wanted this data in a certain way and TLT is doing/done that. Everyone needs to relax They have the funds now to get to an AA. :-)


<< Previous
Bullboard Posts
Next >>